Introduction
============

Esophageal cancer (EC) is the 8th most common cancer worldwide and the 6th most common cause of death from cancer ([@ref-12]). The incidences vary widely in different countries and regions. To date, approximately 53.8% and 51.9% of all ECs occurred and died in China ([@ref-28]; [@ref-12]). Esophageal adenocarcinoma is the most common malignancy in the West. In China, however, esophageal squamous cell carcinoma (ESCC) is the predominant subtype ([@ref-19]). Radical esophagectomy remains the most effective therapy for patients with EC. However, the prognosis for EC remains poor ([@ref-3]; [@ref-9]). Therefore, it is very important to find more and more useful and effective prognostic indicators for patients with EC.

Over the past few decades, a number of prognostic factors for EC have been identified, including tumor length, vessel invasion, lymph node status (N stage), depth of invasion (T stage), TNM stage and other serum biomarkers, such as squamus cell carcinoma antigen (SCCA) and carcinoembryonic antigen (CEA) ([@ref-22]; [@ref-30]; [@ref-11]). Inflammation plays an important role in cancer progression and prognosis ([@ref-2]; [@ref-17]). C-reactive protein (CRP), as a most sensitive inflammatory biomarker, has been confirmed in a series of cancers to predict the prognosis, including patients with EC ([@ref-27]; [@ref-20]; [@ref-23]). In addition, there are other parameters like neutrophil and lymphocyte that are easy-to-measure inflammatory markers ([@ref-10]).

Mean platelet volume (MPV) is recognized as a hallmark for platelet count (PC) activation ([@ref-16]). Several studies showed that MPV and PC are associated with mortality in cardiovascular disease, such as ischemic cardiovascular disease and acute myocardial infarction ([@ref-13]; [@ref-1]). Moreover, recent studies have shown that the ratio for MPV to PC (MPV/PC) is associated with prognosis in some malignancies, such as hepatocellular carcinoma and lung cancer ([@ref-7]; [@ref-15]; [@ref-21]). However, the role for MPV/PC ratio in ESCC is still controversial. Furthermore, controversy exists concerning the optimal cut-off points for MPV/PC to predict the prognosis of ESCC. Therefore, the purpose of our study here was to explore the prognostic role of MPV/PC ratio in patients with ESCC.

Patients and Methods
====================

From January 2007 to December 2010 at the Department of Thoracic Surgery, Zhejiang Cancer Hospital, a retrospective study was conducted including 277 resectable ESCC patients. The exclusion criteria were as follows: (1) patients who received preoperative treatment, such as chemotherapy and/or radiotherapy; (2) patients who had any form of acute or chronic inflammatory diseases or infections; (3) patients who had systemic diseases, and (4) those diagnosed with distant metastases. Written informed consent for the collection of specimen and other medical information were obtained from all patients before surgery. The current study was approved by the Ethics Committees of Zhejiang Cancer Hospital (IRB Approval No. IRB-2018-130).

The main clinical characteristics, such as age, gender, tumor location (upper, middle and lower), tumor length, vessel invasion, differentiation (well, moderate and poor) and tumor stage (T stage, N stage and TNM stage), were retrospectively reviewed and collected. The tumor length was defined as the long diameter for pathological specimens. Blood samples were obtained within one week prior to surgery to measure the neutrophil (Neu), MPV, PC, CRP and CEA levels. MPV/PC was defined as MPV to PC ratio. Neu/PC was defined as Neu to PC ratio. The levels of Neu, MPV and PC were measured by automated blood cell counter (Sysmex XE-2100; Sysmex, Kobe, Japan). Serum levels of CRP were determined by latex-enhanced homogeneous immunoassay (Hitachi 917; Skill, Munich, Germany). Serum levels of CEA were measured using enzyme immunoassay kits (Abbott, Chicago, IL, USA). The AJCC/UICC TNM staging system (the 7th edition) was utilized to classify the stage for this study ([@ref-25]).

All the above patients were followed-up postoperatively (regularly evaluated every 3--6 months). The assessment included physical examination, blood tumor markers and computed tomography scan. In this study, we conducted a cancer-specific survival (CSS) to analyze the prognosis of patients with ESCC. The mean follow-up for patients was 45 months.

Statistical analyses
--------------------

In the current study, the optimal cut-off values for Neu, MPV, PC, MPV/PC ratio, and Neu/PC ratio were calculated by the X-tile program ([@ref-6]). The receiver operator characteristic (ROC) curves were also created to show the candidate cut-off points. The comparisons between the X-tile plot and ROC curve were performed. The areas under the curve (AUC) for Neu, MPV, PC, MPV/PC and Neu/PC were calculated and compared by the ROC curve. The chi-squared tests were used to compare the MPV/PC ratio, MPV and PC. The CSS curves were generated by the Kaplan--Meier method. Univariate analyses were performed with log-rank test. Multivariate analyses with cox proportional hazards regression model were utilized to analyze prognostic factors for CSS. SPSS 20.0 (SPSS Inc., Chicago, IL, USA) was utilized to perform the statistical analyses. R 3.2.3 software (Institute for Statistics and Mathematics, Vienna, Austria) was also utilized to conduct the nomogram model by Harrell's concordance index (c-index) ([@ref-14]).

Results
=======

There were 37 (13.4%) women and 240 (86.6%) men in all 277 patients with the mean age of 59.2 ± 7.8 years (36-80 years). In the current study, the mean values for Neu, MPV, PC, MPV/PC and Neu/PC were 4.2 ± 1.5 (giga/l) (range 1.5--9.5 giga/l), 9.3 ± 1.3 (fl) (range 6.7--12.9 fl), 232 ± 72 (giga/l) (range 60-473 giga/l), 0.04 ± 0.02 (range 0.02--0.14), and 0.020 ± 0.010 (range 0.0053--0.0667), respectively. The histograms of the preoperative MPV/PC ratio, MPV and PC are shown in [Fig. 1](#fig-1){ref-type="fig"}.

![The histograms of the MPV (A), PC (B) and MPV/PC ratio (C).](peerj-07-7246-g001){#fig-1}

According to the X-tile program, the optimum cut-off points for MPV, PC, MPV/PC, Neu and Neu/PC ratio were 8.5 (fl), 200 (giga/l), 0.04, 4.2 (giga/l) and 0.02, respectively ([Fig. 2](#fig-2){ref-type="fig"}). According to the optimum cut-off points of the above values, patients then were divided into 2 groups (MPV ≤8.5 fl and \>8.5 fl; PC ≤200 giga/l and \>200 giga/l; MPV/PC ratio ≤0.04 and \>0.04). Clinicopathologic characters for the above values (MPV/PC ratio, MPV and PC) were shown in [Table 1](#table-1){ref-type="table"}. The levels of MPV/PC ratio were significantly correlated with the CRP levels (*P* = 0.029).

![X-tile analyses.\
X-tile plots of the training sets are shown in A, D, G, J, M, with plots of matched validation sets shown in the smaller inset. The optimal cut-off points highlighted by the black circle in A, D, G, J and M are shown on the histograms of the entire cohort (B, E, H, K, N) and Kaplan-Meier plots (C, F, I, L, O). According to the X-tile program, the optimum cut-off points for MPV (A--C), PC (D--F), MPV/PC (G--I), Neu (J--L) and Neu/PC ratio (M--O) were 8.5 (fl), 200 (giga/l), 0.04, 4.2 (giga/l) and 0.02, respectively.](peerj-07-7246-g002){#fig-2}
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###### Comparison of baseline clinical characteristics in ESCC.

![](peerj-07-7246-g006)

                      Total   MPV (fl)   *P* value   PC (giga/l)   *P* value   MPV/PC   *P* value               
  ------------------- ------- ---------- ----------- ------------- ----------- -------- ----------- ----- ----- ---------
  Age (years)                                        0.704                              0.221                   0.488
  ≤60                 158     51         107                       55          103                  81    77    
  \>60                119     41         78                        50          69                   66    53    
  Gender                                             0.521                              0.271                   0.629
  Female              37      14         23                        11          26                   21    16    
  Male                240     78         162                       94          146                  126   114   
  Tumor length (cm)                                  0.246                              0.020                   0.087
  ≤3.0                78      30         48                        38          40                   35    43    
  \>3.0               199     62         137                       67          132                  112   87    
  CRP (mg/l)                                         0.031                              0.152                   0.029
  ≤10.0               200     74         126                       81          119                  98    102   
  \>10.0              77      18         59                        24          53                   49    28    
  Tumor location                                     0.242                              0.096                   0.057
  Upper               16      7          9                         10          6                    4     12    
  Middle              127     36         91                        44          83                   72    55    
  Lower               134     49         85                        51          83                   71    63    
  Vessel invasion                                    0.744                              0.097                   0.111
  Negative            232     78         154                       83          149                  128   104   
  Positive            45      14         31                        22          23                   19    26    
  Differentiation                                    0.927                              0.826                   0.454
  Well                43      15         28                        16          27                   25    18    
  Moderate            179     58         121                       70          109                  90    89    
  Poor                55      19         36                        19          36                   32    23    
  T stage                                            0.106                              0.313                   0.425
  T1                  50      22         28                        18          32                   28    22    
  T2                  49      20         29                        24          25                   21    28    
  T3                  154     44         110                       56          98                   86    68    
  T4                  24      6          18                        7           17                   12    12    
  N stage                                            0.054                              0.720                   0.899
  N0                  150     60         90                        61          89                   78    72    
  N1                  74      21         53                        27          47                   39    35    
  N2                  32      7          25                        10          22                   19    13    
  N3                  21      4          17                        7           14                   11    10    
  TNM stage                                          0.003                              0.357                   0.546
  I                   69      31         38                        31          38                   33    36    
  II                  92      35         57                        34          58                   52    40    
  III                 116     26         90                        40          76                   62    54    
  CEA (ng/ml)                                        0.818                              0.566                   0.954
  ≤5.0                239     80         159                       89          50                   127   112   
  \>5.0               38      12         26                        16          22                   20    18    
  Neu (giga/l)                                       0.249                              0.681                   0.186
  ≤4.2                146     53         93                        57          89                   72    74    
  \>4.2               131     39         92                        48          83                   75    56    
  Neu/PC                                             0.090                              \<0.001                 \<0.001
  ≤0.02               170     50         120                       35          135                  114   56    
  \>0.02              107     42         65                        70          37                   33    74    

**Notes.**

ESCCesophageal squamous cell carcinomaCRPc-reactive proteinMPVmean platelet volumePCplatelet countTNMtumor node metastasisCEAcarcinoembryonic antigenNeuneutrophil

Kaplan--Meier analyses showed that a low MPV/PC ratio level (≤0.04) was associated with poor CSS (*P* \< 0.001). The 5-year CSS was 43.1% in patients with MPV/PC ratio \>0.04, and 22.4% in patients with MPV/PC ratio ≤0.04 ([Fig. 3A](#fig-3){ref-type="fig"}). There were also significantly different for MPV (42.4% vs. 27.0%, *P* = 0.010) and PC (41.0% vs. 26.7%, *P* = 0.009) ([Figs. 3B](#fig-3){ref-type="fig"}--[3C](#fig-3){ref-type="fig"}). In multivariate analyses, we found that MPV/PC ratio was an independent predictor for CSS (*P* \< 0.001) ([Table 2](#table-2){ref-type="table"}). In addition, TNM stage (*P* \< 0.001), CEA (*P* = 0.019), Neu (*P* = 0.007) and CRP (*P* \< 0.001) were other significant prognostic variables by multivariate analyses ([Table 2](#table-2){ref-type="table"}).

![Kaplan--Meier CSS curves.\
Patients with MPV/PC ratio \>0.04 had a significantly better 5-year CSS than patients with MPV/PC ratio ≤0.04 (43.1% vs. 22.4%, *P* \< 0.001; (A). The 5-year CSS were also significantly different for MPV (42.4% vs. 27.0%, *P* = 0.010; (B) and PC (41.0% vs. 26.7%, *P* = 0.009; (C). When we set the cut-off points using ROC curve, the MPV/PC ratio (42.7% vs. 23.5%, *P* \< 0.001; (D), MPV (51.7% vs. 26.7%, *P* = 0.001; (E), and PC (41.8% vs. 19.3%, *P* \< 0.001; (F) were also associated with CSS.](peerj-07-7246-g003){#fig-3}
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###### Univariate and multivariate analyses for cancer-specific survival.

![](peerj-07-7246-g007)

                     CSS (%)   *P* value   Univariate analysis    *P* value   Multivariate analysis   *P* value
  ------------------ --------- ----------- ---------------------- ----------- ----------------------- -----------
  Age (years)                  0.412                              0.417       --                      --
  ≤60                33.5                  1.000                                                      
  \>60               30.3                  1.127 (0.845--1.502)                                       
  Gender                       0.114                              0.120       --                      --
  Female             45.9                  1.000                                                      
  Male               30.0                  1.445 (0.909--2.298)                                       
  Tumor length                 0.003                              0.004       --                      --
  ≤3 cm              42.3                  1.000                                                      
  \> 3 cm            28.1                  1.642 (1.173--2.297)                                       
  Tumor location               0.336                              0.342       --                      --
  Upper/Middle       35.7                  1.000                                                      
  Lower              28.4                  1.149 (0.863--1.530)                                       
  Vessel invasion              0.003                              0.003       --                      --
  Negative           35.3                  1.000                                                      
  Positive           15.6                  1.710 (1.197--2.444)                                       
  Differentiation              0.054                              0.058       --                      --
  Well/Moderate      33.8                  1.000                                                      
  Poor               25.5                  1.398 (0.989--1.978)                                       
  T stage                      \<0.001                            \<0.001     --                      --
  T1-2               45.5                  1.000                                                      
  T3-4               24.7                  1.898 (1.382--2.606)                                       
  N stage                      \<0.001                            \<0.001     --                      --
  N0                 49.3                  1.000                                                      
  N1-3               11.8                  2.852 (2.120--3.836)                                       
  TNM stage                    \<0.001                            \<0.001                             \<0.001
  I                  58.0                  1.000                              1.000                   
  II                 38.9                  1.966 (1.259--3.067)   0.003       1.825 (1.164--2.861)    0.009
  III                13.8                  3.799 (2.490--5.736)   \<0.001     3.624 (2.362--5.560)    \<0.001
  Adjuvant therapy             0.085                              0.090       --                      --
  No                 35.6                  1.000                                                      
  Yes                24.4                  1.297 (0.960--1.753)                                       
  CRP (mg/l)                   \<0.001                            \<0.001                             \<0.001
  ≤ 10.0             39.5                  1.000                              1.000                   
  \> 10.0            13.0                  2.066 (1.526--2.798)               1.994 (1.461--2.722)    
  MPV (fl)                     0.019                              0.021       --                      --
  ≤ 8.5              41.3                  1.000                                                      
  \> 8.5             27.6                  1.451 (1.057--1.992)                                       
  PC (giga/l)                  0.009                              0.011       \-                      \-
  ≤ 200              41.0                  1.000                                                      
  \> 200             26.7                  1.488 (1.097--2.019)                                       
  MPV/PC                       \<0.001                            \<0.001                             \<0.001
  \> 0.04            43.1                  1.000                              1.000                   
  ≤ 0.04             22.4                  1.861 (1.386--2.498)               1.823 (1.347--2.469)    
  CEA (ng/ml)                  0.027                              0.031                               0.019
  ≤ 5.0              33.5                  1.000                              1.000                   
  \> 5.0             23.7                  1.549 (1.042--2.302)               1.613 (1.082--2.407)    
  Neu (giga/l)                 \<0.001                            \<0.001                             0.007
  ≤ 4.2              43.8                  1.000                              1.000                   
  \> 4.2             19.1                  1.945 (1.455--2.600)               1.512 (1.120--2.040)    
  Neu/PC                       0.223                              0.229       --                      --
  ≤ 0.02             35.3                  1.000                                                      
  \> 0.02            27.1                  1.195 (0.894--1.597)                                       

**Notes.**

ESCCesophageal squamous cell carcinomaCRPc-reactive proteinMPVmean platelet volumePCplatelet countTNMtumor node metastasisCEAcarcinoembryonic antigenNeuneutrophilCIconfidence intervalHRhazard ratio

We also created ROC curves to show the candidate cut-off points. The cut-off values for Neu, MPV, PC, MPV/PC, and Neu/PC ratio by the ROC curves were 4.25 (giga/l), 8.25(fl), 243.5 (giga/l), 0.0410, and 0.0213, respectively ([Fig. 4](#fig-4){ref-type="fig"}). The candidate cut-off points and the area under ROC curve (AUC) are shown in [Table 3](#table-3){ref-type="table"}. When we set the cut-off points using ROC curve, the MPV/PC ratio (42.7% vs. 23.5%, *P* \< 0.001), MPV (51.7% vs. 26.7%, *P* = 0.001), and PC (41.8% vs. 19.3%, *P* \< 0.001) were also associated with CSS (D-F) ([Figs. 3D](#fig-3){ref-type="fig"}--[3F](#fig-3){ref-type="fig"}). In multivariate analyses, MPV/PC ratio was still an independent predictor for CSS (*P* \< 0.001) ([Table 4](#table-4){ref-type="table"}).

![ROC curve analysis.\
The cut-off values for Neu, MPV, PC, MPV/PC, and Neu/PC ratio by the ROC curves were 4.25 (giga/l), 8.25(fl), 243.5 (giga/l), 0.0410, and 0.0213, respectively.](peerj-07-7246-g004){#fig-4}

Moreover, we wanted to predict the survival risk (CSS) for patients with ESCC, a nomogram model was conducted including age, gender, TNM, CEA, Neu, MPV/PC ratio and CRP for CSS ([Fig. 5](#fig-5){ref-type="fig"}). From this model, the probability of survival for ESCC patients could be predicted (c-index = 0.72).
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###### Comparison of AUC areas for the prognostic factors in ESCC.

![](peerj-07-7246-g008)

           Cut-off   Sensibility   Specificity   AUC     95% CI         *P*-value
  -------- --------- ------------- ------------- ------- -------------- -----------
  MPV/PC   0.0410    62.9          61.7          0.608   0.548--0.666   Reference
  MPV      8.25      84.6          34.8          0.609   0.549--0.667   0.9834
  PC       243.5     50.0          74.2          0.648   0.588--0.704   0.0181
  Neu      4.25      53.7          76.4          0.689   0.630--0.743   0.1123
  Neu/PC   0.0213    38.3          74.2          0.543   0.482--0.603   0.3269

**Notes.**

ESCCesophageal squamous cell carcinomaAUCarea under the curveMPVmean platelet volumePCplatelet countNeuneutrophil
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###### Multivariate analyses in ESCC with the cut-off values by ROC curve.

![](peerj-07-7246-g009)

                                     HR (95% CI)            *P*-value
  ---------------------------------- ---------------------- -----------
  CRP (mg/l) (\>10.0 vs. ≤10.0)      2.060 (1.511--2.807)   \<0.001
  TNM stage                                                 
  II vs. I                           1.816 (1.160--2.844)   0.009
  III vs. I                          3.529 (2.298--5.417)   \<0.001
  MPV/PC ( ≤0.0410 vs. \>0.0410)     1.728 (1.275--2.342)   \<0.001
  CEA (ng/ml) ( \>5.0 vs. ≤5.0)      1.636 (1.097--2.438)   0.016
  Neu (giga/l) ( \>4.25 vs. ≤4.25)   1.553 (1.150--2.096)   0.004

**Notes.**

ESCCesophageal squamous cell carcinomaCSScancer-specific survivalCRPc-reactive proteinMPVmean platelet volumePCplatelet countTNMtumor node metastasisCEAcarcinoembryonic antigenNeuneutrophilCIconfidence intervalHRhazard ratio

![Nomogram model for prediction.\
The Harrell's c-index for CSS prediction was 0.72. A nomogram predicts survival prediction based on MPV/PC and other prognostic factors in patients with ESCC. The nomogram is used by totalling the points identified at the top of the scale for each independent factor. This total point score is then identified on the total points scale to determine the probability of risk prediction (A) and survival prediction (B).](peerj-07-7246-g005){#fig-5}

Discussion
==========

Our study demonstrated some important findings: (1) MPV/PC ratio was a strong predictor of CSS; (2) MPV/PC ratio, but not MPV or PC, was a useful predictive indicator. This study used X-tile program and ROC curves as candidate cut-off points. The comparisons between the X-tile plot and ROC curve were performed. The cut-off values were similar between the X-tile and ROC curve. Moreover, our study is also the first attempt to predict the survival risk by a nomogram model based on MPV/PC ratio.

Platelet activation has been demonstrated as a common phenomenon in some cardiovascular diseases ([@ref-13]; [@ref-1]). To assess the platelet activation status, MPV and PC are two main aspects. Moreover, studies have shown that MPV/PC ratio is associated with prognosis in some malignancies, such as hepatocellular carcinoma and lung cancer ([@ref-7]; [@ref-15]; [@ref-21]). [@ref-7] have shown that the ratio of MPV/PC levels in hepatocellular carcinoma were higher than the control group. [@ref-15] have revealed that MPV/PC ratio was significantly different on survival in lung cancer. However, [@ref-21] showed that increased MPV and increased PC were significant higher than the control group. In their study, however, MPV/PC was not an independent predictor in lung cancer.

MPV is an indicator of platelet activation. [@ref-26] demonstrated that reduced MPV is associated with worse survival outcome in EC. The role for MPV/PC ratio in ESCC patients has not yet been well evaluated. A study reported by [@ref-29] showed that the levels of MPV/PC ratio in ESCC were significantly lower than the healthy group, and which were significantly correlated with the tumor length. In our study, however, the MPV/PC ratio was not significantly correlated with the tumor length (*P* = 0.087). In addition, they revealed that decreased MPV and MPV/PC ratio were significantly associated with locally advanced ESCC. In our study, MPV was not a significant prognostic factor by multivariate analyses. Recently, [@ref-31] initial conducted a COP-MPV (combination of MPV and PC) model to predict the prognosis in ESCC. They revealed that COP-MPV was a useful independent predictor, but not for MPV or PC. As everyone knows, MPV and PC may be influenced by a variety of other non-cancer related conditions, the potential basis could be decreased by the MPV to PC ratio (MPV/PC). Therefore, the role of the MPV/PC ratio would be more reliable than the effect of either MPV or PC. In the current study, a low MPV/PC ratio level (≤ 0.04) was associated with poor CSS (*P* \< 0.001) and was confirmed by multivariate analyses (*P* \< 0.001).

In previous studies, controversy exists about the optimum cut-off point for MPV/PC ratio to predict prognosis. [@ref-7] demonstrated that 0.0491 might be the optimum cut-off point for MPV/PC ratio in hepatocellular carcinoma according to the ROC curve. [@ref-15] and [@ref-21] also conducted the ROC curve analyses to calculate the optimum cut-off point for MPV/PC in lung cancer. They concluded that the optimum cut-off points for MPV/PC ratio were 0.40873 and 0.47424, respectively. Recently, [@ref-6] initial conducted a program to explore the optimum cut-off point (X-tile plot). In our study, according to their method, 0.04 was the optimum cut-off point for MPV/PC ratio. We also created ROC curves to show the candidate cut-off points. When we set the cut-off point using ROC curve, the MPV/PC ratio was also associated with CSS. In multivariate analyses, MPV/PC ratio was still an independent predictor for CSS.

The mechanism between MPV/PC ratio and cancer remains unknown. Inflammation and cancer are closely related ([@ref-2]; [@ref-17]). As is well known, platelets can release a variety of cytokines, such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), which have an important role in regulating angiogenesis ([@ref-4]; [@ref-5]; [@ref-8]). The inflammation will be inevitably caused by chemotherapy and/or radiation. Therefore, we analyze the role of MPV/PC ratio in ESCC patients without neoadjuvant chemotherapy and/or radiation.

Limitations should be acknowledged in this study. The major limitations of this study are small samples and its retrospective character. Moreover, patients who received preoperative chemotherapy and/or radiotherapy were excluded, which might have influenced the result in the current study. On the one hand, neoadjuvant treatment will have a side effect on MPV and PC. On the other hand, neoadjuvant treatment can improve cancer survival for locally advanced EC, but not for early stage EC ([@ref-24]; [@ref-18]). In addition, we did not set up a validation group to verify the conclusion. Thus, the results of our study are expected more large-sample trials to confirm in future.

Conclusion
==========

In summary, we found that the ratio of MPV/PC is a potential prognostic biomarkers in patients with ESCC.
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